For questions, or to speak with someone directly, please call:
1-888-824-0200
To request an appointment, please use our secure online form. A representative will contact you within one to two business days to help you schedule an appointment.
Schedule an Appointment on Zocdoc
Current patients may also use MyChart to request an appointment.
The patient portal is not for medical emergencies. If you have a medical emergency, call 911.
For help with MyChart, call us at 1-844-442-4278.
For help with Ingalls Care Connection, call us at 1-708-915-4357 or email portalsupport@ingalls.org.
Find a Clinical Trial
This phase II trial studies how well brentuximab vedotin and nivolumab work in treating participants with stage I-II classic Hodgkin lymphoma. Monoclonal antibodies, such as brentuximab vedotin and nivolumab, may interfere with the ability of tumor cells to grow and...
Interventional / Recruiting / NCT03712202
This research study will evaluate the safety and efficacy of a study drug called TGR-1202 in combination with another study drug called ublituximab with or without bendamustine and TGR-1202 alone as a possible treatment for Non-Hodgkin's Lymphoma (NHL) that has...
Interventional / Recruiting / NCT02793583
This phase II trial studies how well nivolumab with or without varlilumab works in treating patients with aggressive B-cell lymphomas that have come back or do not respond to treatment. Immunotherapy with monoclonal antibodies, such as varlilumab and nivolumab, may...
Interventional / Recruiting / NCT03038672
This study will examine the safety profile of SEA-CD40 given alone and in combination with pembrolizumab. The study will test increasing doses of SEA-CD40 given at least every 3 weeks to small groups of patients. The goal is to find...
Interventional / Recruiting / NCT02376699
A multicenter, open-label expanded access protocol for the treatment of subjects with relapsed/refractory large B-cell lymphoma.
Expanded Access / Recruiting / NCT03153462
This is a randomized, open label, multicenter phase III trial comparing the efficacy, safety, and tolerability of tisagenlecleucel to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline...
Interventional / Recruiting / NCT03570892
This randomized phase II trial studies how well obinutuzumab with or without umbralisib, lenalidomide, or combination chemotherapy work in treating patients with grade I-IIIa follicular lymphoma that has come back or does not respond to treatment. Immunotherapy with...
Interventional / Recruiting / NCT03269669
The purpose of this study is to assess the safety, tolerability, and efficacy when combining MK-3475 and INCB024360 in subjects with certain cancers. This study will be conducted in 2 phases, Phase 1 and Phase 2.
Interventional / Recruiting / NCT02178722
This is a multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in adult patients with relapsed or refractory FL.
Interventional / Recruiting / NCT03568461
The purposes of this study are to: 1) assess the safety and tolerability and 2) establish a preliminary recommended Phase 2 dose (RP2D) and/or a maximum tolerated dose (MTD) or a maximum administered dose (MAD) of MK-2118 when administered via...
Interventional / Recruiting / NCT03249792
